-
Posted by
Two Blokes Apr 24 -
Filed in
Stock
-
4 views
VICTORIA, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere\u2122 technology designed to optimize drug delivery for applications with significant unmet need, today announced that the Company's management and scientific teams will present at the following investor and scientific conferences in April and May: Osteoarthritis Research Society International World Congress April 24-27, 2025 Dr. Phil Conaghan, a member of the Company's OA Clinical Advisory Board, will be presenting a poster on the Company's behalf at the Osteoarthritis Research Society International (“OARSI”) World Congress 2025, being held April 24-27, 2025 in Incheon (Seoul), South Korea. Poster Details Poster Title: EP-104IAR (extended-release intra-articular injection of fluticasone propionate) shows sustained pain response for subjects with moderate baseline pain and BMI less than 30 in SPRINGBOARD, a Phase 2, randomized, 24-week study of osteoarthritis of the knee.
